Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
(Thomson Reuters ONE) -
Novartis International AG /
Six leading scientists to receive prestigious Novartis Prizes for Immunology at
16th International Congress of Immunology
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and
Harald von Boehmer for demonstrating that the ability of the immune system
to discriminate "self" from "non-self" is acquired in the thymus.
* The Clinical Immunology Prize is awarded to Zelig Eshhar, Carl June and
Steven Rosenberg for their work on the cellular immune therapy of cancer
using CAR-T-cells.
Basel, August 15, 2016 - Today Novartis announced that six scientists will
receive the 2016 Novartis Prizes for Immunology at the upcoming 16(th)
International Congress of Immunology (ICI) in Melbourne, Australia on Aug
22, 2016.
The Novartis Prizes for Immunology are awarded every three years for
breakthrough contributions to the fields of basic and clinical immunology. Each
of the two Prize categories is endowed for CHF 100,000 and can be shared by up
to three scientists.
"This year's prize recipients are scientific pioneers who have delivered novel
concepts and opened the door to uncharted fields at the forefront of
immunological research," said Dhavalkumar D. Patel, M.D., Ph.D, Head of Research
Europe and Global Head, Autoimmunity, Transplantation and Inflammation research
at the Novartis Institutes for BioMedical Research. "We are proud to sponsor
these prizes as part of our continued commitment to supporting innovative
research in immunology."
The winners were selected by an independent jury of seven world-class
immunologists for their groundbreaking research into the biology of the immune
system. Each recipient has had a tremendous impact on the understanding of T-
cell mediated mechanisms such as tolerance (basic immunology) and how these
principles can be exploited to design therapeutic approaches (clinical
immunology).
The Novartis Prize for Basic Immunology 2016 is shared by John Kappler (National
Jewish Health, USA), Philippa Marrack (National Jewish Health, USA) and Harald
von Boehmer (Emeritus, Harvard Medical School, USA) for their work in
demonstrating how the immune system is able to discriminate "self" from "non-
self" through a process in the thymus based on positive and negative selection
via T-cell receptor mediated recognition of peptide-MHC complexes.
The Novartis Prize for Clinical Immunology 2016 is awarded to Zelig Eshhar
(Weizmann Institute of Science, Israel), Carl June (University of Pennsylvania,
USA) and Steven Rosenberg (National Institutes of Health, USA) for their work on
the pre-clinical and clinical development as well as technological application
of cellular immune therapy using Chimeric Antigen Receptor-T cells (CAR-T-cells)
for diseases such as cancer.
"Immune disorders destroy the lives of many and increased research in this field
is vital," said Hidde Ploegh, Jury chair, "these prestigious awards recognize
the outstanding contributions made by the world's top scientists. It is so
important that we recognize and reward these exceptional scientists who have
paved the way for future research and treatment."
For more information on the prizes go to:
http://www.novartisimmunologyprizes.com/
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "to receive,"
"will," "upcoming," "opened the door," "commitment," or similar expressions.
Such forward-looking statements reflect the current views of the Group regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any future
results expressed or implied by such statements. These expectations could be
affected by, among other things, risks and factors referred to in the Risk
Factors section of Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Novartis is providing the information in
this press release as of this date and does not undertake any obligation to
update it in the future.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Sandra Schluechter
Novartis Global Media Relations Novartis Institutes for BioMedical Research
+41 61 324 7999 (direct) +41 61 696 6806 (direct)
+41 79 593 4202 (mobile) +41 79 826 0196 (mobile)
eric.althoff(at)novartis.com sandra.schluechter(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2035166/757955.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#2035166]
Unternehmensinformation / Kurzprofil:
Datum: 15.08.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 489010
Anzahl Zeichen: 7553
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 363 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
